Two Sigma Advisers LP Sells 18,300 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Two Sigma Advisers LP trimmed its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 34.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,400 shares of the company's stock after selling 18,300 shares during the period. Two Sigma Advisers LP owned 0.07% of Prestige Consumer Healthcare worth $2,686,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kestra Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $27,000. CIBC Private Wealth Group LLC raised its holdings in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares during the period. Headlands Technologies LLC bought a new stake in Prestige Consumer Healthcare during the fourth quarter valued at about $40,000. Johnson Financial Group Inc. acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $93,000. Finally, Huntington National Bank increased its stake in shares of Prestige Consumer Healthcare by 133.2% in the fourth quarter. Huntington National Bank now owns 1,481 shares of the company's stock worth $116,000 after purchasing an additional 846 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock traded up $1.30 on Friday, hitting $85.78. The company's stock had a trading volume of 330,734 shares, compared to its average volume of 298,487. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The firm has a market cap of $4.24 billion, a P/E ratio of 20.09, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. The company has a fifty day moving average price of $83.58 and a 200-day moving average price of $82.39.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.02. The firm had revenue of $296.52 million during the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The firm's quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $1.02 EPS. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares of the company's stock, valued at $1,544,130. The trade was a 8.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PBH. Oppenheimer raised their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Canaccord Genuity Group raised their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Finally, Royal Bank of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.